Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integra Lifesciences HoldingsIART +4.98%71 EBITDA Margin % is 14.92% as of Mar. 2026, which is 8% below its 10-year median of 16.21. GuruFocus rates IART with a GF Score™ of 71/100 and a GF Value™ of $23.81 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Integra Lifesciences Holdings ranks worse than 71.2% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Integra Lifesciences Holdings EBITDA Margin % Related Terms
Integra Lifesciences Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IART vs ATEC, AHCO, INSP: EBITDA Margin % Comparison
For the Medical Devices subindustry, Integra Lifesciences Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (IART) has a EBITDA Margin % of 14.92% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Integra Lifesciences Holdings and its competitors. This is near median its historical median of 16.21. According to the industry distribution chart, Integra Lifesciences Holdings ranks #581 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 71.2%.
Is Integra Lifesciences Holdings' EBITDA Margin % too high?
Integra Lifesciences Holdings' current EBITDA Margin % of 14.92% is near median its 10-year median of 16.21. The Medical Devices & Instruments industry median EBITDA Margin % is 7.46. Integra Lifesciences Holdings' value of 14.92% is 100.1% above this industry median. Based on the distribution chart, Integra Lifesciences Holdings ranks #581 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Integra Lifesciences Holdings has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' EBITDA Margin % compare to ATEC and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #581 out of 816 companies for EBITDA Margin %. This places Integra Lifesciences Holdings in the lower half of its industry. The industry median EBITDA Margin % is 7.46. Integra Lifesciences Holdings' value of 14.92% is 100.1% above this benchmark. While the company's 10-year median is 16.21 vs. the industry median of 7.46, Integra Lifesciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integra Lifesciences Holdings's current EBITDA Margin % of 14.92% is 100.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Integra Lifesciences Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integra Lifesciences Holdings's current EBITDA Margin % is 14.92%, which is near median its own 10-year median of 16.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.81, compared to a current price of $19.72 — trading 17.2% below its estimated fair value. The current EBITDA Margin % is 14.92%, which is near median its 10-year median of 16.21 and 100.1% above the Medical Devices & Instruments industry median of 7.46. Integra Lifesciences Holdings' overall GF Score™ is 71/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current EBITDA Margin % is 14.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (IART) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of $19.72 is trading 17.2% below its estimated GF Value™ of $23.81.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for IART:
EBITDA Margin %: 14.92% (near median its 10-year median of 16.21)
GF Value™: $23.81 vs. price of $19.72 (17.2% below fair value)
Industry Position: 100.1% above the Medical Devices & Instruments median (#581 of 816)
No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Business Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
71GF Score
Get the complete analysis for IART
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IART has been successfully added to your 
